FIELD: pharmacology.
SUBSTANCE: invention relates to a pharmaceutical composition for oral administration, comprising a core containing hydrocortisone and a carrier, and a delayed release polymer layer in contact with the said core. The core contains microcrystalline cellulose in an amount of 75-85% by composition weight. The delayed release polymer is a mixture of a polymer (1) having a composition of poly(methacrylic acid, methyl methacrylate) at a ratio of 1:1, and a polymer (2) having a composition of poly(methacrylic acid, methyl methacrylate) at a ratio of 1:2. Polymers (1) and (2) are presented at a ratio of 1:4 and are taken in an amount of 6-7% by composition weight. Also a method for composition manufacture and its use for treating adrenal insufficiency is described.
EFFECT: release of hydrocortisone in accordance with the circadian release of cortisol to reproduce natural cortisol release.
39 cl, 7 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION COMPRISING HYDROCORTISONE | 2014 |
|
RU2664678C2 |
| CFR RECEPTOR ANTAGONISTS FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | 2015 |
|
RU2812318C2 |
| CFR RECEPTOR ANTAGONISTS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA | 2015 |
|
RU2718918C2 |
| CHRONOTHERAPEUTIC PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2571067C2 |
| METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT | 2013 |
|
RU2649807C2 |
| CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA | 2019 |
|
RU2824490C2 |
| EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF | 2012 |
|
RU2603471C2 |
| CORTICOSTEROIDS FOR JOINT PAIN TREATMENT | 2011 |
|
RU2642279C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FEBUXOSTAT | 2011 |
|
RU2602188C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DIACEREIN | 2009 |
|
RU2542461C2 |
